The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Real-world prognostic model for overall survival (OS) in patients (pts) with advanced urothelial cancer (aUC) treated with immune checkpoint inhibitors (ICI).
 
Ali Raza Khaki
Stock and Other Ownership Interests - Pfizer; Procter & Gamble; Walgreens Boots Alliance
 
Leonidas Nikolaos Diamantopoulos
No Relationships to Disclose
 
Natalie J. Miller
No Relationships to Disclose
 
Mehmet Asim Bilen
Consulting or Advisory Role - Eisai; EMD Serono; Exelixis; Genomic Health; Janssen; Nektar; Sanofi
Research Funding - Advanced Accelerator Applications (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Genentech/Roche (Inst); Incyte (Inst); Nektar (Inst); Peleton (Inst); Pfizer (Inst); Seagen (Inst); Tricon Pharmaceuticals (Inst); Xencor (Inst)
 
Victor Sacristan Santos
No Relationships to Disclose
 
Rafael Morales-Barrera
Consulting or Advisory Role - AstraZeneca; MSD; Sanofi
Speakers' Bureau - Asofarma; MSD Oncology
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Bayer; Clovis Oncology; Johnson & Johnson; Lilly; MSD; Roche/Genentech; Sanofi
 
Michael Edward Devitt
Consulting or Advisory Role - Bayer
 
Ariel Ann Nelson
No Relationships to Disclose
 
Evan Shreck
No Relationships to Disclose
 
Hussein Assi
No Relationships to Disclose
 
Roubini Zakopoulou
No Relationships to Disclose
 
Alejo Rodriguez-Vida
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Janssen Oncology; MSD; Novartis; Pfizer; Roche; Sanofi
Research Funding - MSD (Inst); Pfizer (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb; Janssen Oncology; Pfizer; Roche
 
Mark Lythgoe
No Relationships to Disclose
 
Alexandra Drakaki
Employment - Kyn therapeutics (I)
Leadership - Kyn therapeutics (I)
Stock and Other Ownership Interests - Alimera Sciences (I); Athos Therapeutics (I); Kyn therapeutics (I); Urogen pharma (I)
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Kyn therapeutics; RADMETRIX; Seagen
Research Funding - Kite/Gilead
Patents, Royalties, Other Intellectual Property - My significant other has 5 patents with UCLA. (I)
Travel, Accommodations, Expenses - AstraZeneca; Lilly; Seagen
 
Monika Joshi
Consulting or Advisory Role - Sanofi
Research Funding - AstraZeneca (Inst); Pfizer (Inst)
 
Pedro Isaacsson Velho
Honoraria - Bayer
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Pfizer
Research Funding - Bristol-Myers Squibb; Pfizer (Inst)
Expert Testimony - Bayer
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Merck; Merck Serono; Pfizer
 
Lucia Alonso
No Relationships to Disclose
 
Matt D. Galsky
Stock and Other Ownership Interests - Rappta Therapeutics
Consulting or Advisory Role - Aileron Therapeutics; Astellas Pharma; AstraZeneca; BioMotiv; Bristol-Myers Squibb; Dendreon; Dracen; Dragonfly Therapeutics; EMD Serono; Genentech; GlaxoSmithKline; Incyte; Inovio Pharmaceuticals; Janssen; Lilly; Merck; Novartis; NuMab; Pfizer; Seagen
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Genentech/Roche (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - METHODS AND COMPOSITIONS FOR TREATING CANCER AND RELATED METHODS. MOUNT SINAI SCHOOL OF MEDICINE July 2012 Application number: 20120322792
 
Guru Sonpavde
Honoraria - UpToDate
Consulting or Advisory Role - Agensys; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; EMD Serono; Exelixis; Genentech; Janssen; Merck; Novartis; Sanofi
Speakers' Bureau - Clinical Care Options/NCCN; Onclive; Physicans' Education Resource; Research to Practice
Research Funding - AstraZeneca; Bayer (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); Janssen (Inst); Merck (Inst); Onyx (Inst); Pfizer (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
Other Relationship - Astellas Pharma; AstraZeneca; Bavarian Nordic; Boehringer Ingelheim; Bristol-Myers Squibb; Debiopharm Group
 
Petros Grivas
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Driver, Inc; EMD Serono; Exelixis; Foundation Medicine; Genzyme; GlaxoSmithKline; HERON; Janssen; Merck; Mirati Therapeutics; Pfizer; QED Therapeutics; Roche; Seagen
Research Funding - Bavarian Nordic (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Debiopharm Group (Inst); Immunomedics (Inst); Pfizer (Inst)